TwinBeech Capital’s Arcturus Therapeutics ARCT Stock Holding History

TwinBeech Capital’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,125	Closed	-$275K	–	570
2021 Q2	$275K	Buy	8,125 +2,325	+40%	+$78.7K	0.03%	380
2021 Q1	$240K	Sell	5,800 -1,083	-16%	-$64.6K	0.04%	411
2020 Q4	$299K	Buy	+6,883	New	+$466K	0.05%	364

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

TwinBeech Capital's ARCT Position: Q3 2021 in Review

TwinBeech Capital sold out of Arcturus Therapeutics (ARCT) in Q3 2021, closing a stake of 8,125 shares — an estimated $275K sold.

TwinBeech Capital first reported a position in ARCT in Q4 2020 and held it in 3 quarters. The position peaked at $299K in Q4 2020. 156 funds tracked by Wall St. Rank hold ARCT as of Q3 2021.

TwinBeech Capital reported no remaining Arcturus Therapeutics position as of Q3 2021 after selling out during the quarter.
TwinBeech Capital sold 8,125 Arcturus Therapeutics shares in Q3 2021, an estimated $275K.
TwinBeech Capital first reported a position in Arcturus Therapeutics in Q4 2020 and held it in 3 quarters.
TwinBeech Capital's Arcturus Therapeutics position peaked at $299K in Q4 2020.
156 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2021.

Based on TwinBeech Capital's 13F filing for Q3 2021, filed 15 Nov 2021.